ReviewInternational journal of nanomedicine2025
Advances of Drug-Loaded Microsphere Technology for Targeted Immunotherapy Against Prostate Cancer.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering microspheres for breast cancer: integrating tumor modeling, diagnostics, and targeted treatment.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating advanced prostate cancer presents challenges like therapy resistance and systemic toxicity. Combining drug-loaded microspheres with immunotherapy, such as PD-1 inhibitors, and targeted therapy like PARP inhibitors has transformed the treatment of prostate cancer. This review focuses on microcatheter-assisted techniques that allow for precise embolization using 100-300 μm microspheres and enable sustained drug release, resulting in an objective response rate (ORR) of 35-52% in clinical trials. Important advancements include pulsed injection protocols at 0.5 mL/min under cone beam CT (CBCT) guidance and biomarker-driven stratification, focusing on a PD-L1 combined positive score (CPS) of ≥10 and homologous recombination repair (HRR) mutations. The PROEMBOL trial shows a 98.1% rate of immediate hemostasis, and combination therapies with PARP inhibitors increase the median progression-free survival (PFS) to 14.2 months for patients with HRR mutations. Future efforts must prioritize standardized technical protocols and real-world validation of long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.